Question-and-Answer Session
Operator
(Operator Instructions) Your first question comes from Ron Epstein - Merrill Lynch.
Ron Epstein - Merrill Lynch
So when we think about medical going forward, and we were hoping that things would have been stabilized at this point, can you give us any more color on how we should think about it, how we should model it, that kind of thing?
Robert Brady
Yes, well, I think your model for this year ought to be what we just described because that’s what we think is most likely to happen, $24 million a quarter in the next couple of quarters and then a couple of million in operating profit. We think that next year will be stronger in operating profit. When we began this initiative, as I said, we believed that this would be a market that would provide faster than the average sales growth and nice profitability.
Now I think what we’ve learned is that in the acquisitions we’ve made, we have acquired some very strong products. We are, however, getting acquainted with the channels of distribution in the clinic market for intravenous pumps and the pain management pumps, which was the McKinley product line, and in the enteral pumps.
And we have some things to learn; it’s a new market for us, and as I mentioned in the prepared remarks, in this particular quarter, we had some unusual expenses, which we don’t think will recur. I’m still optimistic that this is going to turn out to be a strong product line for us. And I think we just have to be patient.
We bought ZEVEX halfway through last year. We’re in the process of combining these, the ZEVEX and what was the ZEVEX and the Curlin organization into a coordinated unit with one engineering organization, one sales management outfit, and one operations organization. And we’re making real progress.
I can tell you I spent last week in Europe and visited a couple prospective customers, companies that are not yet customers for the products that we are talking about and they have a very high regard for the products that we have. So, when I say these are strong products, it’s not just my opinion. It’s the opinion of people who actually have been in the market.
Ron Epstein - Merrill Lynch
With the award on the multi-year on the V-22 to Textron and Boeing, how big an opportunity is that for Moog as we walk out over the next year or so?
- To read the full transcript on Seeking Alpha, click here »
